<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f3344ca-4170-1e1b-e063-6394a90a426b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MONTELUKAST SODIUM TABLETS safely and effectively. See full prescribing information for MONTELUKAST SODIUM TABLETS.
 <br/>
MONTELUKAST SODIUM tablets, for oral use
 <br/>
Initial U.S. Approval: 1998
</title>
   <effectiveTime value="20250228"/>
   <setId root="5d71088b-b0fa-4bf0-a6e7-6163bd9e0dd4"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="815564528"/>
            <name>Quallent Pharmaceuticals Health LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="650452530"/>
                        <name>Hetero Labs Limited Unit V</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="82009-009" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f334720-2d03-22d6-e063-6394a90a52cf"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250228"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="82009-009" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Montelukast
</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Montelukast</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="U1O3J18SFL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MONTELUKAST SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="MHM278SD3E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MONTELUKAST</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="82009-009-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220607"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA202843" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220607"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="brown" xsi:type="CE">
                              <originalText>Biege</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48350" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SQUARE" xsi:type="CE">
                              <originalText>rounded square</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">114;I</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="rcm">
               <id root="2f3344ca-4171-1e1b-e063-6394a90a426b"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Boxed Warning                                                                              04/2020 
    <br/>  Indications and Usage (1.3, 1.4)                                                    02/2021 
    <br/>  Dosage and Administration (2.1, 2.2, 2.3, 2.4)                              02/2021 
    <br/>   Warnings and Precautions (5.1)                                                   02/2021 
    <br/>
                           <br/>     
   </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="2f3344ca-4172-1e1b-e063-6394a90a426b"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS</title>
               <text>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">WARNING:SERIOUS NEUROPSYCHIATRIC EVENTS 
   <br/>
                     </content>
                     <br/>
                     <content styleCode="bold">Seriousneuropsychiatric (NP) events have been reported with the use of montelukast sodium. The types of events reported were highly variable,and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide).The mechanisms underlying NP events associated with montelukast sodium use are currently not well understood
  
   <content styleCode="italics">[see WarningsandPrecautions (
   
    <linkHtml href="#Section_5.6">5.1</linkHtml>)].
  
   </content>
                        <br/>  Becauseof the risk of NP events, the benefits of montelukast sodium may not outweigh the risks in some patients, particularly when the symptomsof disease may be mild and adequately treated with alternative therapies. Reserve use of montelukast sodium for patients with allergic rhinitiswho have an inadequate response or intolerance to alternative therapies
  
   <content styleCode="italics">[see Indications and Usage (
   
    <linkHtml href="#Section_1.3">1.3</linkHtml>)].
  
   </content>In patients with asthmaorexercise-induced bronchoconstriction, consider the benefits and risks before prescribing montelukast sodium. 
   <br/>  Discussthe benefits and risks of montelukast sodium with patients and caregivers when prescribing montelukast sodium. Advise patients and/orcaregivers to be alert for changes in behavior or new NP symptoms when taking montelukast sodium. If changes in behavior are observed,or ifnew NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue montelukast sodium andcontact a healthcare provider immediately [
  
   <content styleCode="italics">see Warnings and Precautions (
   
    <linkHtml href="#Section_5.6">5.1</linkHtml>)].
  
   </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">    WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">• Serious neuropsychiatric events have been reported in patients taking montelukast sodium
  
     <linkHtml href="#Section_5.6">(5.1).</linkHtml>
                              <br/>  • Discuss benefits and risks of montelukast sodium with patients and caregivers 
  
     <linkHtml href="#Section_5.6">(5.1).</linkHtml>
                              <br/>  • Monitor for neuropsychiatric symptoms in patients taking montelukast sodium
  
     <linkHtml href="#Section_5.6">(5.1).</linkHtml>
                              <br/>  • Discontinue montelukast sodium immediately if neuropsychiatric symptoms occur 
  
     <linkHtml href="#Section_5.6">(5.1).</linkHtml>
                              <br/>  • Because the benefits of montelukast sodium may not outweigh the potential risk of neuropsychiatric symptoms in patients with allergic rhinitis, reserve use for patients who have an inadequate response or intolerance to alternative therapies (
  
     <linkHtml href="#Section_1.3">1.3</linkHtml>,
  
     <linkHtml href="#Section_5.6">5.1).</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="2f3344ca-4173-1e1b-e063-6394a90a426b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20240505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <paragraph>Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: 
    <br/>  • Prophylaxis and chronic treatment of asthma in patients 15 years of   age and older
 
    <linkHtml href="#Section_1.1">(1.1).</linkHtml>
                           <br/>  • Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older
 
    <linkHtml href="#Section_1.2">(1.2).</linkHtml>
                           <br/>  • Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 15 years of age and older, and perennial allergic rhinitis (PAR) in patients 15 years of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies
 
    <linkHtml href="#Section_1.3">(1.3).</linkHtml>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                           <br/>  • Not indicated to treat an acute asthma attack (5.2).

   </paragraph>
                        <br/>
                        <br/>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="2f3344ca-4174-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Asthma</title>
                     <text>
                        <br/>
                        <paragraph>Montelukast sodium tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and adolescents 15 years of age and older.</paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="2f3344ca-4175-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Exercise-Induced Bronchoconstriction (EIB)</title>
                     <text>
                        <paragraph>Montelukast sodium tablets are indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older. 
  <br/>
                           <content styleCode="italics">
                              <br/>   
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.3">
                     <id root="2f3344ca-4176-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Allergic Rhinitis</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="xmChange">Montelukast sodiumtablets are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 15 years of age and older and perennial allergic rhinitis in patients 15 yearsof age and older. Because the benefits of montelukast sodium tablets may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis
 
   <content styleCode="italics">[see Warnings and Precautions</content>
                              <content styleCode="italics">
                                 <linkHtml href="#Section_5.6">(5.1)],</linkHtml>
                              </content> reserve use for patients who have an inadequate response orintolerance to alternative therapies.

  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.4">
                     <id root="2f3344ca-4177-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Limitations of Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Montelukastsodium tablets are not indicated for the treatment of an acute asthma attack.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="2f3344ca-4178-1e1b-e063-6394a90a426b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Administration (by indications): 
    <br/>  • Asthma: Once daily in the evening for patients 15 years and older (
 
    <linkHtml href="#Section_2.1">2.1</linkHtml>).  
    <br/>  • Acute prevention of EIB: One tablet at least 2 hours before exercise for patients 15 years of age and older (
 
    <linkHtml href="#Section_2.2">2.2</linkHtml>). 
    <br/>  • Seasonal allergic rhinitis: Once daily for patients 15 years and older (
 
    <linkHtml href="#Section_2.3">2.3</linkHtml>). 
    <br/>  • Perennial allergic rhinitis: Once daily for patients 15 years and older (
 
    <linkHtml href="#Section_2.3">2.3</linkHtml>). 
    <br/>  Dosage (by age): 
    <br/>  • 15 years and older: one 10 mg  tablet (
 
    <linkHtml href="#Section_2">2</linkHtml>).  
    <br/>  Patients with both asthma and allergic rhinitis should take only one dose daily in the evening
 
    <linkHtml href="#Section_2.4">(2.4).</linkHtml>
                        </paragraph>
                        <br/>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="2f3344ca-4179-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Asthma</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="xmChange">Forasthma, administer montelukast sodium tablets orally once daily in the evening, with or without food. There have been no clinical trials in patients with asthma toevaluate the relative efficacy of morning versus evening dosing. 
   <br/>  The following doses arerecommended: 
   <br/>
                              <content styleCode="bold">Table 1: RecommendedDosage in Asthma</content>
                           </content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="403.123">
                           <col width="64.9290663147476%"/>
                           <col width="35.0709336852524%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Age</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Dose</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Adult and adolescent
    
     <content>patients</content>15 years of age and
    
     <content>older</content>
                                    <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">one 10 mg tablet 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold"> </content>Patientswho miss a dose should take the next dose at their regular time and should not take 2 doses at the same time.

  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="2f3344ca-417a-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Exercise-Induced Bronchoconstriction (EIB)</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="xmChange">Forprevention of EIB, administer a single dose of montelukast sodium tablets orally at least 2 hours, before exercise. 
   <br/>  The following doses arerecommended: 
   <br/>   
 
   <content styleCode="bold">Table 2: RecommendedDosage in Exercise-Induced Bronchoconstriction (EIB)</content>
                              <br/>            

  </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="64.92%"/>
                           <col width="35.08%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top"> 
    
     <content styleCode="bold">Age</content>
                                    <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 
    
     <content styleCode="bold">Dose</content>
                                    <br/>   
   
    </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"> 
    
     <content>Adult</content>and adolescent patients 15 years of age 
     <br/>   
    
     <content>and older</content>
                                    <br/>   
   
    </td>
                                 <td align="justify" styleCode="Rrule" valign="top"> 
    
     <content>one</content>10 mg tablet 
     <br/>   
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>An additional dose of montelukast sodium tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. 
  <br/>  Daily administration of montelukast sodium tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.
 </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="2f3344ca-417b-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Allergic Rhinitis</title>
                     <text>
                        <br/>
                        <paragraph>For allergic rhinitis, administer montelukast sodium tablets orally once daily without regard to time of food ingestion. Time of administration in patients with allergic rhinitis can be individualized to suit patient needs. 
  <br/>  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:
 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3: RecommendedDosage in Seasonal Allergic Rhinitis</content>
                        </paragraph>
                        <br/>
                        <paragraph>          </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="64.92%"/>
                           <col width="35.08%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top"> 
    
     <content styleCode="bold">Age</content>
                                    <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 
    
     <content styleCode="bold">Dose</content>
                                    <br/>   
   
    </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"> 
    
     <content>Adult</content>and adolescent patients 15 years of age 
     <br/>   
    
     <content>and older</content>
                                    <br/>   
   
    </td>
                                 <td align="justify" styleCode="Rrule" valign="top"> 
    
     <content>one 10 mg tablet</content>
                                    <br/>   
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <content styleCode="xmChange">The following doses for the treatment of symptoms of perennial allergic rhinitisare recommended:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4: Recommended Dosage in Perennial AllergicRhinitis</content>
                        </paragraph>
                        <br/>
                        <paragraph>          </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="64.92%"/>
                           <col width="35.08%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top"> 
    
     <content styleCode="bold">Age</content>
                                    <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 
    
     <content styleCode="bold">Dose</content>
                                    <br/>   
   
    </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"> 
    
     <content>Adult and</content>adolescent patients 15 years of age 
     <br/>
                                    <content>and older</content>
                                    <br/>   
   
    </td>
                                 <td align="justify" styleCode="Rrule" valign="top"> 
    
     <content>one 10 mg tablet</content>
                                    <br/>   
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="xmChange">Patients who miss a dose should take the next dose at their regular timeand should not take 2 doses at the same time.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="2f3344ca-417c-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Asthma and Allergic Rhinitis</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="xmChange">For patients with both asthma and allergic rhinitis, administer only one montelukast sodium tablets dose orally once daily in the evening. 
   <br/>  Patients whomiss a doseshould takethe next dose at their regular time and should not take 2 doses at the same time.
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="2f3344ca-417d-1e1b-e063-6394a90a426b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Montelukast sodium film-coated tablets, USP 10 mg are beige, rounded square-shaped, film-coated tablets debossed with ‘I’ on one side and ‘114’ on the other side. </item>
                  </list>
               </text>
               <effectiveTime value="20240505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•  Tablets: 10 mg
 
    <linkHtml href="#Section_3">(3)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="2f3344ca-417e-1e1b-e063-6394a90a426b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <br/>
                  <br/>
                  <paragraph>Montelukast sodium tablets are contraindicated in patients with hypersensitivity to any of its components.</paragraph>
               </text>
               <effectiveTime value="20240505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity to any component of montelukast sodium tablets (
  
     <linkHtml href="#Section_4">4</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="2f3344ca-417f-1e1b-e063-6394a90a426b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•   Do not prescribe montelukast sodium to treat an acute asthma attack
 
    <linkHtml href="#Section_5.1">(5.2).</linkHtml>
                           <br/>  •   Advise patients to have appropriate rescue medication available
 
    <linkHtml href="#Section_5.1">(5.2).</linkHtml>
                           <br/>  •   Inhaled corticosteroid may be reduced gradually. Do not abruptly substitute montelukast sodium for inhaled or oral corticosteroids
 
    <linkHtml href="#Section_5.2">(5.3).</linkHtml>
                           <br/>  •  Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium
 
    <linkHtml href="#Section_5.3">(5.4).</linkHtml>
                           <br/>  •  Systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported. These events have been sometimes associated with the reduction of oral   corticosteroid therapy 
 
    <linkHtml href="#Section_5.5">(5.5</linkHtml>and
 
    <linkHtml href="#Section_6.2">6.2).</linkHtml>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.6">
                     <id root="2f3344ca-4180-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Neuropsychiatric Events</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="xmChange">Serious neuropsychiatric (NP) events have been reported with use of montelukast sodium. These postmarketing reports have been highly variable and included, but were not limited to, agitation,aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities,dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness,somnambulism, suicidal thoughts and behavior (including suicide), tic, and tremor. NP events have been reported in adult, adolescent, and pediatric patients with and without aprevioushistory of psychiatric disorder. NP events have been reported mostly during montelukast sodium treatment, but some were reported aftermontelukastsodium discontinuation. Animal studies showed that montelukast distributes into the brain in rats
 
   <content styleCode="italics">[see Clinical Pharmacology</content>
                              <content styleCode="italics">
                                 <linkHtml href="#Section_12.3">(12.3)];</linkHtml>
                              </content> however, the mechanisms underlying montelukast sodium-associated NPeventsare currently not well understood. Based upon the available data, it is difficult to identify riskfactorsfor or quantify the risk of NP events with montelukast sodium use. 
   <br/>  Because of the risk of NP events, the benefits of montelukast sodium may not outweigh the risks in some patients, particularly when the symptoms of disease may bemildand adequately treated with alternative therapies. Reserve use of montelukast sodium for patients with allergic rhinitis who have an inadequateresponseor intolerance to alternative therapies
 
   <content styleCode="italics">[see Indications and Usage</content>
                              <content styleCode="italics">
                                 <linkHtml href="#Section_1.3">(1.3)].</linkHtml>
                              </content> In patients with asthma or exercise-induced bronchoconstriction, consider the benefits andrisksbefore prescribing montelukast sodium. 
   <br/>  Discuss the benefits and risks of montelukast sodium use with patients and caregivers when prescribing montelukast sodium. Advise patients and/or caregivers to bealertfor changes in behavior or for new NP symptoms when taking montelukast sodium. If changes in behavior are observed, or if new NP symptoms or suicidal thoughtsand/orbehavior occur, advise patients to discontinue montelukast sodium and contact a healthcare provider immediately. In many cases, symptomsresolved after stopping montelukast sodium therapy; however, in some cases symptoms persisted after discontinuation of montelukast sodium. Therefore,continue to monitor and provide supportive care until symptoms resolve. Re-evaluate the benefits and risks of restarting treatment withmontelukastsodium if such events occur.

  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.1">
                     <id root="2f3344ca-4181-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Acute Asthma</title>
                     <text>
                        <br/>
                        <paragraph>Montelukast sodium is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Patients should be advised to have appropriate rescue medication available. Therapy with montelukast sodium can be continued during acute exacerbations of asthma. Patients who have exacerbations of asthma after exercise should have available for rescue a short-acting inhaled β-agonist.</paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="2f3344ca-4182-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Concomitant Corticosteroid Use</title>
                     <text>
                        <paragraph>While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, montelukast sodium should not be abruptly substituted for inhaled or oral corticosteroids.</paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="2f3344ca-4183-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Aspirin Sensitivity</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium. Although montelukast sodium is effective in improving airway function in asthmatics with documented aspirin sensitivity, it has not been shown to truncate bronchoconstrictor response to aspirin and other non-steroidal anti-inflammatory drugs in aspirin-sensitive asthmatic patients
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#Section_14.1">14.1</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="2f3344ca-4184-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Eosinophilic Conditions</title>
                     <text>
                        <br/>
                        <paragraph>Patients with asthma on therapy with montelukast sodium may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These events have been sometimes associated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between montelukast sodium and these underlying conditions has not been established
 
  <content styleCode="italics">[see Adverse Reactions
  
   <linkHtml href="#Section_6.2">(6.2)].</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="2f3344ca-4185-1e1b-e063-6394a90a426b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <br/>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling: 
  <br/>  • Neuropsychiatric Events
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.1</linkHtml>)]
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <paragraph>Most common adverse reactions (incidence ≥5% and greater than placebo listed in descending order of frequency): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis (
 
    <linkHtml href="#Section_6.1">6.1</linkHtml>). 
    <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Quallent Pharmaceuticals Health LLC at 1-877-605-7243 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 
     <br/>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="2f3344ca-4186-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <br/>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the following description of clinical trials experience, adverse reactions are listed regardless of causality assessment. 
  <br/>  The most common adverse reactions (incidence ≥5% and greater than placebo; listed in descending order of frequency) in controlled clinical trials were: upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis. 
  <br/>
                           <content styleCode="underline">Adults and Adolescents 15 Years of Age and Older with Asthma</content>
                           <br/>  Montelukast sodium has been evaluated for safety in approximately 2950 adult and adolescent patients 15 years of age and older in clinical trials. In placebo-controlled clinical trials, the following adverse reactions reported with montelukast sodium occurred in greater than or equal to 1% of patients and at an incidence greater than that in patients treated with placebo: 
  <br/>
                           <content styleCode="bold">Table 5: Adverse Reactions Occurring in ≥1% of Patients with an Incidence Greater than that in Patients Treated with Placebo</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="42.1%"/>
                           <col width="31.58%"/>
                           <col width="26.32%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">   
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Montelukast sodium 
     <br/>   10 mg/day 
     <br/>   (%) 
     <br/>   (n=1955) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Placebo 
     <br/>   (%) 
     <br/>   (n=1180) 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> 
    
     <content styleCode="italics">Body As A Whole</content>
                                    <br/>   
   
    </td>
                                 <td styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                                 <td styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Pain, abdominal 
     <br/>    Asthenia/fatigue 
     <br/>    Fever 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 2.9 
     <br/>   1.8 
     <br/>   1.5 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 2.5 
     <br/>   1.2 
     <br/>   0.9 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule" valign="top">  Trauma 
     <br/>     
     <br/>   
    
     <content styleCode="italics">Digestive System Disorders</content>
                                    <br/>    Dyspepsia 
     <br/>   
   
    </td>
                                 <td rowspan="2" align="center" styleCode="Rrule" valign="top"> 1.0 
     <br/>
                                    <br/>    
     <br/>
                                    <br/>    
     <br/>
                                    <br/>    
     <br/>
                                    <br/>    
     <br/>  2.1 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>    
     <br/>  0.8 
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top"> 1.1 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Pain, dental 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.7 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.0 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Gastroenteritis, infectious 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.5 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 0.5 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">   
     <br/>   
    
     <content styleCode="italics">Nervous System/Psychiatric</content>
                                    <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Headache 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 18.4 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 18.1 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Dizziness 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.9 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.4 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">   
     <br/>   
    
     <content styleCode="italics">Respiratory System Disorders</content>
                                    <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Influenza 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 4.2 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 3.9 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Cough 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 2.7 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 2.4 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Congestion, nasal 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.6 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.3 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">   
     <br/>   
    
     <content styleCode="italics">Skin/Skin Appendages Disorder</content>
                                    <br/>     
     <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  Rash 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.6 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.2 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">   
     <br/>   
    
     <content styleCode="italics">Laboratory Adverse</content>
                                    <content styleCode="italics">Reactions</content>* 
     <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  ALT increased 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 2.1 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 2.0 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  AST increased 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.6 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.2 
     <br/>   
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">  Pyuria 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.0 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 0.9 
     <br/>   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>* Number of patients tested (montelukast sodium and placebo, respectively): ALT and AST, 1935, 1170; pyuria, 1924, 1159. 
  <br/>  The frequency of less common adverse reactions was comparable between montelukast sodium and placebo. 
  <br/>  The safety profile of montelukast sodium, when administered as a single dose for prevention of EIB in adult and adolescent patients 15 years of age and older, was consistent with the safety profile previously described for montelukast sodium. 
  <br/>  Cumulatively, 569 patients were treated with montelukast sodium for at least 6 months, 480 for one year, and 49 for two years in clinical trials. With prolonged treatment, the adverse reaction profile did not significantly change. 
  <br/>
                           <content styleCode="underline">Adults and Adolescents 15 Years of Age and Older with Seasonal Allergic Rhinitis</content>
                           <br/>  Montelukast sodium has been evaluated for safety in 2199 adult and adolescent patients 15 years of age and older in clinical trials. Montelukast sodium administered once daily in the morning or in the evening had a safety profile similar to that of placebo. In placebo-controlled clinical trials, the following reaction was reported with montelukast sodium with a frequency ≥1% and at an incidence greater than placebo: upper respiratory infection, 1.9% of patients receiving montelukast sodium vs. 1.5% of patients receiving placebo. In a 4-week, placebo-controlled clinical study, the safety profile was consistent with that observed in 2-week studies. The incidence of somnolence was similar to that of placebo in all studies. 
  <br/>
                           <content styleCode="underline">Adults and Adolescents 15 Years of Age and Older with Perennial Allergic Rhinitis</content>
                           <br/>  Montelukast sodium has been evaluated for safety in 3357 adult and adolescent patients 15 years of age and older with perennial allergic rhinitis of whom 1632 received montelukast sodium in two, 6-week, clinical studies. Montelukast sodium administered once daily had a safety profile consistent with that observed in patients with seasonal allergic rhinitis and similar to that of placebo. In these two studies, the following reactions were reported with montelukast sodium with a frequency ≥1% and at an incidence greater than placebo: sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, and increased ALT. The incidence of somnolence was similar to that of placebo.

 </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="2f3344ca-4187-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <br/>
                        <paragraph>The following adverse reactions have been identified during post-approval use of montelukast sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 
  <br/>
                           <content styleCode="underline">Blood and lymphatic system disorders</content>
                           <br/>  increased bleeding tendency, thrombocytopenia 
  <br/>
                           <content styleCode="underline">Immune system disorders</content>
                           <br/>  hypersensitivity reactions including anaphylaxis, hepatic eosinophilic infiltration 
  <br/>
                           <content styleCode="underline">Psychiatric disorders</content>
                           <br/>  including, but not limited to, agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal thinking and behavior (including suicide), tic, and tremor
 
  <content styleCode="italics">[see Boxed Warning, Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.1</linkHtml>)]
 
  </content>
                           <br/>
                           <content styleCode="underline">Nervous system disorders</content>
                           <br/>  drowsiness, paraesthesia/hypoesthesia, seizures 
  <br/>
                           <content styleCode="underline">Cardiac disorders</content>
                           <br/>  palpitations 
  <br/>
                           <content styleCode="underline">Respiratory, thoracic and mediastinal disorders</content>
                           <br/>  epistaxis, pulmonary eosinophilia 
  <br/>
                           <content styleCode="underline">Gastrointestinal disorders</content>
                           <br/>  diarrhea, dyspepsia, nausea, pancreatitis, vomiting 
  <br/>
                           <content styleCode="underline">Hepatobiliary disorders</content>
                           <br/>  Cases of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium. Most of these occurred in combination with other confounding factors, such as use of other medications, or when montelukast sodium was administered to patients who had underlying potential for liver disease such as alcohol use or other forms of hepatitis. 
  <br/>
                           <content styleCode="underline">Skin and subcutaneous tissue disorders</content>
                           <br/>  angioedema, bruising, erythema multiforme, erythema nodosum, pruritus, Stevens-Johnson syndrome/toxic epidermal necrolysis, urticaria 
  <br/>
                           <content styleCode="underline">Musculoskeletal and connective tissue disorders</content>
                           <br/>  arthralgia, myalgia including muscle cramps 
  <br/>
                           <content styleCode="underline">Renal and urinary disorders</content>
                           <br/>  enuresis in children 
  <br/>
                           <content styleCode="underline">General disorders and administration site conditions</content>
                           <br/>  edema 
  <br/>  Patients with asthma on therapy with montelukast sodium may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These reactions have been sometimes associated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.5">5.5</linkHtml>)]. 
   <br/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="2f3344ca-4188-1e1b-e063-6394a90a426b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <br/>
                  <paragraph>No dose adjustment is needed when montelukast sodium is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers 
 
  <content styleCode="italics">[see Clinical Pharmacology
  
   <linkHtml href="#Section_12.3">(12.3)].</linkHtml>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240505"/>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="2f3344ca-4189-1e1b-e063-6394a90a426b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240505"/>
               <component>
                  <section ID="Section_8.1">
                     <id root="2f3344ca-418a-1e1b-e063-6394a90a426b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>  Available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not established a drug-associated risk of major birth defects
 
  <content styleCode="italics">[see Data].</content>In animal reproduction studies, no adverse developmental effects were observed with oral administration of montelukast to pregnant rats and rabbits during organogenesis at doses approximately 100 and 110 times, respectively, the maximum recommended human daily oral dose (MRHDOD) based on AUCs
 
  <content styleCode="italics">[see Data].</content>
                           <br/>  The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 
  <br/>
                           <content styleCode="underline">Clinical Considerations</content>
                           <br/>
                           <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                           <br/>  Poorly or moderately controlled asthma in pregnancy increases the maternal risk of perinatal adverse outcomes such as preeclampsia and infant prematurity, low birth weight, and small for gestational age. 
  <br/>
                           <content styleCode="underline">Data</content>
                           <br/>
                           <content styleCode="italics">Human Data</content>
                           <br/>  Published data from prospective and retrospective cohort studies have not identified an association with montelukast sodium use during pregnancy and major birth defects. Available studies have methodologic limitations, including small sample size, in some cases retrospective data collection, and inconsistent comparator groups. 
  <br/>
                           <content styleCode="italics">Animal Data</content>
                           <br/>  In embryo-fetal development studies, montelukast administered to pregnant rats and rabbits during organogenesis (gestation days 6 to 17 in rats and 6 to 18 in rabbits) did not cause any adverse developmental effects at maternal oral doses up to 400 and 300 mg/kg/day in rats and rabbits, respectively (approximately 100 and 110 times the AUC in humans at the MRHDOD, respectively).

 </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="2f3344ca-418b-1e1b-e063-6394a90a426b"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>  A published clinical lactation study reports the presence of montelukast in human milk. Data available on the effects of the drug on infants, either directly
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#Section_8.4">8.4</linkHtml>)]
 
  </content>or through breast milk, do not suggest a significant risk of adverse reactions from exposure to montelukast sodium. The effects of the drug on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for montelukast sodium and any potential adverse reactions on the breastfed infant from montelukast sodium or from the underlying maternal condition.

 </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="2f3344ca-418c-1e1b-e063-6394a90a426b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <br/>
                        <paragraph>The safety and effectiveness in pediatric patients below the age of 12 months with asthma, 6 months with perennial allergic rhinitis, and 6 years with exercise-induced bronchoconstriction have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="2f3344ca-418d-1e1b-e063-6394a90a426b"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <br/>
                        <paragraph>Of the total number of subjects in clinical studies of montelukast, 3.5% were 65 years of age and over, and 0.4% were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. The pharmacokinetic profile and the oral bioavailability of a single 10 mg oral dose of montelukast are similar in elderly and younger adults. The plasma half-life of montelukast is slightly longer in the elderly. No dosage adjustment in the elderly is required.</paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="2f3344ca-418e-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <br/>
                        <paragraph>No dosage adjustment is recommended in patients with mild-to-moderate hepatic insufficiency [
 
  <content styleCode="italics">see Clinical Pharmacology (
  
   <linkHtml href="#Section_12.3">12.3)].</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="2f3344ca-418f-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <br/>
                        <paragraph>No dosage adjustment is recommended in patients with renal insufficiency
 
  <content styleCode="italics">[see Clinical Pharmacology
  
   <linkHtml href="#Section_12.3">(12.3)].</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="2f3344ca-4190-1e1b-e063-6394a90a426b"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>No specific information is available on the treatment of overdosage with montelukast sodium. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required. It is not known whether montelukast is removed by peritoneal dialysis or hemodialysis.</paragraph>
               </text>
               <effectiveTime value="20240505"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="2f3344ca-4191-1e1b-e063-6394a90a426b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <br/>
                  <paragraph>Montelukast sodium USP, the active ingredient in montelukast sodium tablets USP, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT
 
  <sub>1</sub>receptor. 
  <br/>  Montelukast sodium USP is described chemically as [
 
  <content styleCode="italics">R</content>-(
 
  <content styleCode="italics">E</content>)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt. 
  <br/>  The empirical formula is C
 
  <sub>35</sub>H
 
  <sub>35</sub>CINNaO
 
  <sub>3</sub>S, and its molecular weight is 608.17. The structural formula is:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Montelukast sodium USP is a hygroscopic, optically active, white or almost white powder. Montelukast sodium USP is freely soluble in water and methylene chloride, freely soluble to very soluble in alcohol. 
  <br/>  Each 10 mg film-coated montelukast sodium tablet USP contains 10.4 mg montelukast sodium USP, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, mannitol and microcrystalline cellulose. The tablets are coated with opadry yellow which contains carnauba wax, hydroxypropyl cellulose, hypromellose, red iron oxide, titanium dioxide and yellow iron oxide. 
  <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20240505"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>montelukaststructure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="montelukaststructure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="2f3344ca-4192-1e1b-e063-6394a90a426b"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240505"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="2f3344ca-4193-1e1b-e063-6394a90a426b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <br/>
                        <paragraph>The cysteinyl leukotrienes (LTC
 
  <sub>4</sub>, LTD
 
  <sub>4</sub>, LTE
 
  <sub>4</sub>) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT
 
  <sub>1</sub>) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis. 
  <br/>  Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT
 
  <sub>1</sub>receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD
 
  <sub>4</sub>at the CysLT
 
  <sub>1</sub>receptor without any agonist activity.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="2f3344ca-4194-1e1b-e063-6394a90a426b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <br/>
                        <paragraph>Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD
 
  <sub>4</sub>in asthmatics. Doses as low as 5 mg cause substantial blockage of LTD
 
  <sub>4</sub>-induced bronchoconstriction. In a placebo-controlled, crossover study (n=12), montelukast sodium inhibited early- and late-phase bronchoconstriction due to antigen challenge by 75% and 57%, respectively. 
  <br/>  The effect of montelukast sodium on eosinophils in the peripheral blood was examined in clinical trials. In patients with asthma aged 2 years and older who received montelukast sodium, a decrease in mean peripheral blood eosinophil counts ranging from 9% to 15% was noted, compared with placebo, over the double-blind treatment periods. In patients with seasonal allergic rhinitis aged 15 years and older who received montelukast sodium, a mean increase of 0.2% in peripheral blood eosinophil counts was noted, compared with a mean increase of 12.5% in placebo-treated patients, over the double-blind treatment periods; this reflects a mean difference of 12.3% in favor of montelukast sodium. The relationship between these observations and the clinical benefits of montelukast noted in the clinical trials is not known
 
  <content styleCode="italics">[see Clinical Studies
  
   <linkHtml href="#Section_14">(14)].</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="2f3344ca-4195-1e1b-e063-6394a90a426b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                           <br/>  Montelukast is rapidly absorbed following oral administration. After administration of the 10 mg film-coated tablet to fasted adults, the mean peak montelukast plasma concentration (C
 
  <sub>max</sub>) is achieved in 3 to 4 hours (T
 
  <sub>max</sub>). The mean oral bioavailability is 64%. The oral bioavailability and C
 
  <sub>max</sub>are not influenced by a standard meal in the morning. 
  <br/>  The safety and effectiveness of montelukast sodium in patients with asthma were demonstrated in clinical trials in which the 10 mg film-coated tablet formulation was administered in the evening without regard to the time of food ingestion. The safety and effectiveness of montelukast sodium in patients with seasonal allergic rhinitis were demonstrated in clinical trials in which the 10 mg film-coated tablet was administered in the morning or evening without regard to the time of food ingestion. 
  <br/>  The comparative pharmacokinetics of montelukast when administered as two 5 mg chewable tablets versus one 10 mg film-coated tablet have not been evaluated. 
  <br/>
                           <content styleCode="underline">Distribution</content>
                           <br/>  Montelukast is more than 99% bound to plasma proteins. The steady state volume of distribution of montelukast averages 8 to 11 liters. Orally administered montelukast distributes into the brain in rats. 
  <br/>
                           <content styleCode="underline">Elimination</content>
                           <br/>  The plasma clearance of montelukast averages 45 mL/min in healthy adults. Following an oral dose of radiolabeled montelukast, 86% of the radioactivity was recovered in 5-day fecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile. 
  <br/>  In several studies, the mean plasma half-life of montelukast ranged from 2.7 to 5.5 hours in healthy young adults. The pharmacokinetics of montelukast are nearly linear for oral doses up to 50 mg. During once-daily dosing with 10 mg montelukast, there is little accumulation of the parent drug in plasma (14%).

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                           <br/>  Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and pediatric patients. 
  <br/>
                           <content styleCode="italics">In vitro</content>studies using human liver microsomes indicate that CYP3A4, 2C8, and 2C9 are involved in the metabolism of montelukast. At clinically relevant concentrations, 2C8 appears to play a major role in the metabolism of montelukast. 
  <br/>
                           <content styleCode="underline">Specific Populations</content>
                           <br/>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                           <br/>  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast resulting in 41% (90% CI=7%, 85%) higher mean montelukast AUC following a single 10 mg dose. The elimination of montelukast was slightly prolonged compared with that in healthy subjects (mean half-life, 7.4 hours). No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency. The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated. 
  <br/>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                           <br/>  Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast were not evaluated in patients with renal insufficiency. No dosage adjustment is recommended in these patients. 
  <br/>
                           <content styleCode="italics">Male and Female Patients</content>
                           <br/>  The pharmacokinetics of montelukast are similar in males and females. 
  <br/>
                           <content styleCode="italics">Racial Groups</content>
                           <br/>  Pharmacokinetic differences due to race have not been studied. 
  <br/>
                           <content styleCode="italics">Adolescents and Pediatric Patients</content>
                           <br/>  Pharmacokinetic studies evaluated the systemic exposure of the 10 mg film-coated tablets in young adults and adolescents ≥15 years of age. 
  <br/>  The plasma concentration profile of montelukast following administration of the 10 mg film-coated tablet is similar in adolescents ≥15 years of age and young adults. The 10 mg film-coated tablet is recommended for use in patients ≥15 years of age. 
  <br/>
                           <content styleCode="underline">Drug Interaction Studies</content>
                           <br/>
                           <content styleCode="italics">Theophylline, Prednisone, and Prednisolone</content>
                           <br/>  Montelukast sodium has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no apparent increase in adverse reactions. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, and prednisolone. 
  <br/>  Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state, did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline [predominantly a cytochrome P450 (CYP) 1A2 substrate]. Montelukast at doses of ≥100 mg daily dosed to pharmacokinetic steady state, did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone. 
  <br/>
                           <content styleCode="italics">Oral Contraceptives, Fexofenadine, Digoxin, and Warfarin</content>
                           <br/>  In drug interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), digoxin, and warfarin. Montelukast at doses of ≥100 mg daily dosed to pharmacokinetic steady state did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state did not change the plasma concentration profile of fexofenadine, did not change the pharmacokinetic profile or urinary excretion of immunoreactive digoxin; did not change the pharmacokinetic profile of warfarin (primarily a substrate of CYP2C9, 3A4 and 1A2) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the International Normalized Ratio (INR). 
  <br/>
                           <content styleCode="italics">Thyroid Hormones, Sedative Hypnotics, Non-Steroidal Anti-Inflammatory Agents, Benzodiazepines, and Decongestants</content>
                           <br/>  Although additional specific interaction studies were not performed, montelukast sodium was used concomitantly with a wide range of commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions. These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 
  <br/>
                           <content styleCode="italics">Cytochrome P450 (CYP) Enzyme Inducers</content>
                           <br/>  Phenobarbital, which induces hepatic metabolism, decreased the area under the plasma concentration curve (AUC) of montelukast approximately 40% following a single 10 mg dose of montelukast. No dosage adjustment for montelukast sodium is recommended. It is reasonable to employ appropriate clinical monitoring when potent CYP enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast sodium. 
  <br/>
                           <content styleCode="italics">Effect of Montelukast on Cytochrome P450 (CYP) Enzymes</content>
                           <br/>  Montelukast is a potent inhibitor of CYP2C8
 
  <content styleCode="italics">in vitro</content>. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) in 12 healthy individuals demonstrated that the pharmacokinetics of rosiglitazone are not altered when the drugs are coadministered, indicating that montelukast does not inhibit CYP2C8
 
  <content styleCode="italics">in vivo</content>. Therefore, montelukast is not anticipated to alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide). Based on further
 
  <content styleCode="italics">in vitro</content>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit CYP 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. 
  <br/>
                           <content styleCode="italics">Cytochrome P450 (CYP) Enzyme Inhibitors</content>
                           <br/>
                           <content styleCode="italics">In vitro</content>studies have shown that montelukast is a substrate of CYP 2C8, 2C9, and 3A4. Co-administration of montelukast with itraconazole, a strong CYP 3A4 inhibitor, resulted in no significant increase in the systemic exposure of montelukast. Data from a clinical drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) demonstrated that gemfibrozil, at a therapeutic dose, increased the systemic exposure of montelukast by 4.4-fold. Co-administration of itraconazole, gemfibrozil, and montelukast did not further increase the systemic exposure of montelukast. Based on available clinical experience, no dosage adjustment of montelukast is required upon co-administration with gemfibrozil
 
  <content styleCode="italics">[see Overdosage (
  
   <linkHtml href="#Section_10">10</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="2f3344ca-4196-1e1b-e063-6394a90a426b"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240505"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="2f3344ca-4197-1e1b-e063-6394a90a426b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <br/>
                        <paragraph>No evidence of tumorigenicity was seen in carcinogenicity studies of either 2 years in Sprague-Dawley rats or 92 weeks in mice at oral gavage doses up to 200 mg/kg/day or 100 mg/kg/day, respectively. The estimated exposure in rats was approximately 120 and 75 times the AUC for adults and children, respectively, at the maximum recommended daily oral dose. The estimated exposure in mice was approximately 45 and 25 times the AUC for adults and children, respectively, at the maximum recommended daily oral dose. 
  <br/>  Montelukast demonstrated no evidence of mutagenic or clastogenic activity in the following assays: the microbial mutagenesis assay, the V-79 mammalian cell mutagenesis assay, the alkaline elution assay in rat hepatocytes, the chromosomal aberration assay in Chinese hamster ovary cells, and in the
 
  <content styleCode="italics">in vivo</content>mouse bone marrow chromosomal aberration assay. 
  <br/>  In fertility studies in female rats, montelukast produced reductions in fertility and fecundity indices at an oral dose of 200 mg/kg (estimated exposure was approximately 70 times the AUC for adults at the maximum recommended daily oral dose). No effects on female fertility or fecundity were observed at an oral dose of 100 mg/kg (estimated exposure was approximately 20 times the AUC for adults at the maximum recommended daily oral dose). Montelukast had no effects on fertility in male rats at oral doses up to 800 mg/kg (estimated exposure was approximately 160 times the AUC for adults at the maximum recommended daily oral dose).

 </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="2f3344ca-4198-1e1b-e063-6394a90a426b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20240505"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="2f3344ca-4199-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Asthma</title>
                     <text>
                        <br/>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Adults and Adolescents 15 Years of Age and Older with Asthma</content>
                           <br/>  Clinical trials in adults and adolescents 15 years of age and older demonstrated there is no additional clinical benefit to montelukast doses above 10 mg once daily. 
  <br/>  The efficacy of montelukast sodium for the chronic treatment of asthma in adults and adolescents 15 years of age and older was demonstrated in two (U.S. and Multinational) similarly designed, randomized, 12-week, double-blind, placebo-controlled trials in 1576 patients (795 treated with montelukast sodium, 530 treated with placebo, and 251 treated with active control). The median age was 33 years (range 15 to 85); 56.8% were females and 43.2% were males. The ethnic/racial distribution in these studies was 71.6% Caucasian, 17.7% Hispanic, 7.2% other origins and 3.5% Black. Patients had mild or moderate asthma and were non-smokers who required approximately 5 puffs of inhaled β-agonist per day on an "as-needed" basis. The patients had a mean baseline percent of predicted forced expiratory volume in 1 second (FEV
 
  <sub>1</sub>) of 66% (approximate range, 40 to 90%). The co-primary endpoints in these trials were FEV
 
  <sub>1</sub> and daytime asthma symptoms. In both studies after 12 weeks, a random subset of patients receiving montelukast sodium was switched to placebo for an additional 3 weeks of double-blind treatment to evaluate for possible rebound effects. 
  <br/>  The results of the U.S. trial on the primary endpoint, morning FEV
 
  <sub>1</sub>, expressed as mean percent change from baseline averaged over the 12-week treatment period, are shown in FIGURE 2. Compared with placebo, treatment with one montelukast sodium 10 mg tablet daily in the evening resulted in a statistically significant increase in FEV
 
  <sub>1</sub>percent change from baseline (13.0%-change in the group treated with montelukast sodium vs. 4.2%-change in the placebo group, p&lt;0.001); the change from baseline in FEV
 
  <sub>1</sub>for montelukast sodium was 0.32 liters compared with 0.10 liters for placebo, corresponding to a between-group difference of 0.22 liters (p&lt;0.001, 95% CI 0.17 liters, 0.27 liters). The results of the Multinational trial on FEV
 
  <sub>1</sub>were similar. 
  <br/>
                           <content styleCode="bold">Figure 2: FEV
  
   <sub>1</sub> Mean Percent Change from Baseline (U.S. Trial: Montelukast sodium N=406; Placebo N=270) (ANOVA Model)
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> 
  
   <renderMultiMedia referencedObject="MM2"/>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>The effect of montelukast sodium on other primary and secondary endpoints, represented by the Multinational study is shown in TABLE 6. Results on these endpoints were similar in the US study. 
  <br/>
                           <content styleCode="bold">Table 6:  Effect of Montelukast Sodium on Primary and Secondary Endpoints in a Multinational Placebo-controlled Trial (ANOVA Model)</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="32.06%"/>
                           <col width="7.44%"/>
                           <col width="11.68%"/>
                           <col width="16.98%"/>
                           <col width="6.36%"/>
                           <col width="10.62%"/>
                           <col width="14.86%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">   
     <br/>   
    </td>
                                 <td colspan="3" align="center" styleCode="Rrule" valign="top"> Montelukast sodium 
     <br/>   
    </td>
                                 <td colspan="3" align="center" styleCode="Rrule" valign="top"> Placebo 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"> Endpoint 
     <br/>     
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> N 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Baseline 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Mean Change from Baseline 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> N 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Baseline 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Mean Change from Baseline 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Daytime Asthma Symptoms 
     <br/>   (0 to 6 scale) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 372 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 2.35 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> -0.49* 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 245 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 2.40 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> -0.26 
     <br/>     
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> β-agonist (puffs per day) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 371 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 5.35 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> -1.65* 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 241 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 5.78 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> -0.42 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> AM PEFR (L/min) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 372 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 339.57 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 25.03* 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 244 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 335.24 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 1.83 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> PM PEFR (L/min) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 372 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 355.23 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 20.13* 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 244 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 354.02 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> -0.49 
     <br/>   
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Nocturnal Awakenings (#/week) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 285 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 5.46 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> -2.03* 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 195 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> 5.57 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> -0.78 
     <br/>   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>* p&lt;0.001, compared with placebo 
  <br/>  Both studies evaluated the effect of montelukast sodium on secondary outcomes, including asthma attack (utilization of health-care resources such as an unscheduled visit to a doctor's office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid), and use of oral corticosteroids for asthma rescue. In the Multinational study, significantly fewer patients (15.6% of patients) on montelukast sodium experienced asthma attacks compared with patients on placebo (27.3%, p&lt;0.001). In the US study, 7.8% of patients on montelukast sodium and 10.3% of patients on placebo experienced asthma attacks, but the difference between the two treatment groups was not significant (p=0.334). In the Multinational study, significantly fewer patients (14.8% of patients) on montelukast sodium were prescribed oral corticosteroids for asthma rescue compared with patients on placebo (25.7%, p&lt;0.001). In the US study, 6.9% of patients on montelukast sodium and 9.9% of patients on placebo were prescribed oral corticosteroids for asthma rescue, but the difference between the two treatment groups was not significant (p=0.196). 
  <br/>
                           <content styleCode="underline">Onset of Action and Maintenance of Effects</content>
                           <br/>  In each placebo-controlled trial in adults, the treatment effect of montelukast sodium, measured by daily diary card parameters, including symptom scores, "as-needed" β-agonist use, and PEFR measurements, was achieved after the first dose and was maintained throughout the dosing interval (24 hours). No significant change in treatment effect was observed during continuous once-daily evening administration in non-placebo-controlled extension trials for up to one year. Withdrawal of montelukast sodium in asthmatic patients after 12 weeks of continuous use did not cause rebound worsening of asthma. 
  <br/>
                           <content styleCode="underline">Effects in Patients on Concomitant Inhaled Corticosteroids</content>
                           <br/>  Separate trials in adults evaluated the ability of montelukast sodium to add to the clinical effect of inhaled corticosteroids and to allow inhaled corticosteroid tapering when used concomitantly.  
  <br/>  One randomized, placebo-controlled, parallel-group trial (n=226) enrolled adults with stable asthma with a mean FEV
 
  <sub>1</sub> of approximately 84% of predicted who were previously maintained on various inhaled corticosteroids (delivered by metered-dose aerosol or dry powder inhalers). The median age was 41.5 years (range 16 to 70); 52.2% were females and 47.8% were males. The ethnic/racial distribution in this study was 92.0% Caucasian, 3.5% Black, 2.2% Hispanic, and 2.2% Asian. The types of inhaled corticosteroids and their mean baseline requirements included beclomethasone dipropionate (mean dose, 1203 mcg/day), triamcinolone acetonide (mean dose,  2004 mcg/day), flunisolide (mean dose, 1971 mcg/day), fluticasone propionate (mean dose, 1083 mcg/day), or budesonide (mean dose, 1192 mcg/day). Some of these inhaled corticosteroids were non-U.S.-approved formulations, and doses expressed may not be ex-actuator. The pre-study inhaled corticosteroid requirements were reduced by approximately 37% during a 5- to 7-week placebo run-in period designed to titrate patients toward their lowest effective inhaled corticosteroid dose. Treatment with montelukast sodium resulted in a further 47% reduction in mean inhaled corticosteroid dose compared with a mean reduction of 30% in the placebo group over the 12-week active treatment period (p≤0.05). It is not known whether the results of this study can be generalized to patients with asthma who require higher doses of inhaled corticosteroids or systemic corticosteroids. 
  <br/>  In another randomized, placebo-controlled, parallel-group trial (n=642) in a similar population of adult patients previously maintained, but not adequately controlled, on inhaled corticosteroids (beclomethasone 336 mcg/day), the addition of montelukast sodium to beclomethasone resulted in statistically significant improvements in FEV
 
  <sub>1</sub> compared with those patients who were continued on beclomethasone alone or those patients who were withdrawn from beclomethasone and treated with montelukast or placebo alone over the last 10 weeks of the 16-week, blinded treatment period. Patients who were randomized to treatment arms containing beclomethasone had statistically significantly better asthma control than those patients randomized to montelukast sodium alone or placebo alone as indicated by FEV
 
  <sub>1</sub> daytime asthma symptoms, PEFR, nocturnal awakenings due to asthma, and "as-needed" β-agonist requirements. 
  <br/>  In adult patients with asthma with documented aspirin sensitivity, nearly all of whom were receiving concomitant inhaled and/or oral corticosteroids, a 4-week, randomized, parallel-group trial (n=80) demonstrated that montelukast sodium, compared with placebo, resulted in significant improvement in parameters of asthma control. The magnitude of effect of montelukast sodium in aspirin-sensitive patients was similar to the effect observed in the general population of asthma patients studied. The effect of montelukast sodium on the bronchoconstrictor response to aspirin or other non-steroidal anti-inflammatory drugs in aspirin-sensitive asthmatic patients has not been evaluated
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.3">5.4</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>montelukastfigure2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="montelukastfigure2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="2f3344ca-419a-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Exercise-Induced Bronchoconstriction (EIB)</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Exercise-Induced Bronchoconstriction (Adults and Adolescents 15 years of age and older)</content>
                           <br/>  The efficacy of montelukast sodium, 10 mg, when given as a single dose 2 hours before exercise for the prevention of EIB was investigated in three (U.S. and Multinational), randomized, double-blind, placebo-controlled crossover studies that included a total of 160 adult and adolescent patients 15 years of age and older with EIB. Exercise challenge testing was conducted at 2 hours, 8.5 or 12 hours, and 24 hours following administration of a single dose of study drug (montelukast sodium 10 mg or placebo). The primary endpoint was the mean maximum percent fall in FEV
 
  <sub>1</sub> following the 2 hours post-dose exercise challenge in all three studies (Study A, Study B, and   Study C). In Study A, a single dose of montelukast sodium 10 mg demonstrated a statistically significant protective benefit against EIB when taken 2 hours prior to exercise. Some patients were protected from EIB at 8.5 and 24 hours after administration; however, some patients were not. The results for the mean maximum percent fall at each timepoint in Study A are shown in TABLE 7 and are representative of the results from the other two studies. 
  <br/>
                           <content styleCode="bold">Table 7: Mean Maximum Percent Fall in FEV
  
   <sub>1</sub> Following Exercise Challenge in Study A (N=47) ANOVA Model
 
  </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="39.78%"/>
                           <col width="20.12%"/>
                           <col width="10.74%"/>
                           <col width="29.36%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="bottom"> Time of exercise challenge following medication administration 
     <br/>   
    </td>
                                 <td colspan="2" align="center" styleCode="Rrule" valign="middle"> Mean Maximum percent fall in FEV
    
     <sub>1</sub>
                                    <sup>*</sup>
                                    <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Treatment 
     <br/>   difference % for Montelukast sodium versus 
     <br/>   Placebo 
     <br/>   (95% CI)* 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="bottom">   
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="bottom"> Montelukast sodium 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> Placebo 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">   
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> 2 hours 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 13 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 22 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> -9 (-12, -5) 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> 8.5 hours 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 12 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 17 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> -5 (-9, -2) 
     <br/>   
    </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="bottom"> 24 hours 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="bottom"> 10 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="bottom"> 14 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="bottom"> -4 (-7, -1) 
     <br/>   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*Least squares-mean 
  <br/>  Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.
 </paragraph>
                        <br/>
                        <paragraph>In a 12-week, randomized, double-blind, parallel group study of 110 adult and adolescent asthmatics 15 years of age and older, with a mean baseline FEV
 
  <sub>1</sub> percent of predicted of 83% and with documented exercise-induced exacerbation of asthma, treatment with montelukast sodium, 10 mg, once daily in the evening, resulted in a statistically significant reduction in mean maximal percent fall in FEV
 
  <sub>1</sub>and mean time to recovery to within 5% of the pre-exercise FEV
 
  <sub>1</sub>. Exercise challenge was conducted at the end of the dosing interval (i.e., 20 to 24 hours after the preceding dose). This effect was maintained throughout the 12-week treatment period indicating that tolerance did not occur. Montelukast sodium did not, however, prevent clinically significant deterioration in maximal percent fall in FEV
 
  <sub>1</sub> after exercise (i.e., ≥20% decrease from pre-exercise baseline) in 52% of patients studied. In a separate crossover study in adults, a similar effect was observed after two once-daily 10 mg doses of montelukast sodium.

 </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.3">
                     <id root="2f3344ca-419b-1e1b-e063-6394a90a426b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Allergic Rhinitis (Seasonal and Perennial)</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Seasonal Allergic Rhinitis</content>
                           <br/>  The efficacy of montelukast sodium tablets for the treatment of seasonal allergic rhinitis was investigated in 5 similarly designed, randomized, double-blind, parallel-group, placebo- and active-controlled (loratadine) trials conducted in North America. The 5 trials enrolled a total of 5029 patients, of whom 1799 were treated with montelukast sodium tablets. Patients were 15 to 82 years of age with a history of seasonal allergic rhinitis, a positive skin test to at least one relevant seasonal allergen, and active symptoms of seasonal allergic rhinitis at study entry. 
  <br/>  The period of randomized treatment was 2 weeks in 4 trials and 4 weeks in one trial. The primary outcome variable was mean change from baseline in daytime nasal symptoms score (the average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing) as assessed by patients on a 0 to 3 categorical scale. 
  <br/>  Four of the five trials showed a significant reduction in daytime nasal symptoms scores with montelukast sodium 10 mg tablets compared with placebo. The results of one trial are shown below. The median age in this trial was 35.0 years (range 15 to 81); 65.4% were females and 34.6% were males. The ethnic/racial distribution in this study was 83.1% Caucasian, 6.4% other origins, 5.8% Black, and 4.8% Hispanic. The mean changes from baseline in daytime nasal symptoms score in the treatment groups that received montelukast sodium tablets, loratadine, and placebo are shown in TABLE 9. The remaining three trials that demonstrated efficacy showed similar results. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening. 
  <br/>
                           <content styleCode="bold">Table 9: Effects of Montelukast Sodium on Daytime Nasal Symptoms Score* in a Placebo- and Active-controlled Trial in Patients with Seasonal Allergic Rhinitis (ANCOVA Model)</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="30.2%"/>
                           <col width="14.58%"/>
                           <col width="17.7%"/>
                           <col width="37.5%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> Treatment Group (N) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> Baseline Mean Score 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> Mean Change from Baseline 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Difference Between Treatment and Placebo (95% CI) 
     <br/>   Least-Squares Mean 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> Montelukast Sodium 10 mg (344) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 2.09 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> -0.39 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> -0.13† (-0.21, -0.06) 
     <br/>     
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> Placebo (351) 
     <br/>     
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 2.10 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> -0.26 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> N.A. 
     <br/>     
     <br/>   
    </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> Active ControlP
    
     <sup>‡</sup>
                                    <br/>   (Loratadine 10 mg) (599) 
     <br/>     
     <br/>   
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 2.06 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> -0.46 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">   
     <br/>   -0.24† (-0.31, -0.17) 
     <br/>   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>* Average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing as assessed by patients on a 0 to 3 categorical scale. 
  <br/>
                           <sup>†</sup>  Statistically different from placebo (p≤0.001). 
  <br/>
                           <sup>‡</sup>  The study was not designed for statistical comparison between montelukast sodium and the active control (loratadine). 
  <br/>
                           <content styleCode="underline">Perennial Allergic Rhinitis</content>
                           <br/>  The efficacy of montelukast sodium tablets for the treatment of perennial allergic rhinitis was investigated in 2 randomized, double-blind, placebo-controlled studies conducted in North America and Europe. The two studies enrolled a total of 3357 patients, of whom 1632 received montelukast sodium 10 mg tablets. Patients 15 to 82 years of age with perennial allergic rhinitis as confirmed by history and a positive skin test to at least one relevant perennial allergen (dust mites, animal dander, and/or mold spores), who had active symptoms at the time of study entry, were enrolled. 
  <br/>  In the study in which efficacy was demonstrated, the median age was 35 years (range 15 to 81); 64.1% were females and 35.9% were males. The ethnic/racial distribution in this study was 83.2% Caucasian, 8.1% Black, 5.4% Hispanic, 2.3% Asian, and 1.0% other origins. Montelukast sodium 10 mg tablets once daily was shown to significantly reduce symptoms of perennial allergic rhinitis over a 6-week treatment period (TABLE 10); in this study the primary outcome variable was mean change from baseline in daytime nasal symptoms score (the average of individual scores of nasal congestion, rhinorrhea, and sneezing). 
  <br/>
                           <content styleCode="bold">Table 10: Effects of Montelukast Sodium on Daytime Nasal Symptoms Score* in a Placebo-controlled Trial in Patients with Perennial Allergic Rhinitis (ANCOVA Model)</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="26.04%"/>
                           <col width="15.62%"/>
                           <col width="20.84%"/>
                           <col width="37.5%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> Treatment Group (N) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> Baseline 
     <br/>   Mean Score 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> Mean Change from Baseline 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="top"> Difference Between Treatment and Placebo (95% CI) 
     <br/>   Least-Squares Mean 
     <br/>   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> Montelukast Sodium 
     <br/>   10 mg (1000) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 2.09 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> -0.42 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> - 0.08† (-0.12, -0.04) 
     <br/>   
    </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="middle"> Placebo 
     <br/>   (980) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> 2.10 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> -0.35 
     <br/>     
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> N.A. 
     <br/>   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>* Average of individual scores of nasal congestion, rhinorrhea, sneezing as assessed by patients on a 0 to 3 categorical scale. 
  <br/>
                           <sup>†</sup>Statistically different from placebo (p≤0.001). 
  <br/>  The other 6-week study evaluated montelukast sodium 10 mg (n=626), placebo (n=609), and an active-control (cetirizine 10 mg; n=120). The primary analysis compared the mean change from baseline in daytime nasal symptoms score for montelukast sodium vs. placebo over the first 4 weeks of treatment; the study was not designed for statistical comparison between montelukast sodium and the active-control. The primary outcome variable included nasal itching in addition to nasal congestion, rhinorrhea, and sneezing. The estimated difference between montelukast sodium and placebo was -0.04 with a 95% CI of (-0.09, 0.01). The estimated difference between the active-control and placebo was -0.10 with a 95% CI of (-0.19, -0.01).

 </paragraph>
                     </text>
                     <effectiveTime value="20240505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="2f3344ca-419c-1e1b-e063-6394a90a426b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Montelukast sodium tablets, USP 10 mg are beige, rounded square-shaped, film-coated tablets debossed with ‘I’ on one side and ‘114’ on the other side. They are supplied as follows: 
  <br/>            Bottles of 1000 Tablets                 NDC 82009-009-10 
  <br/>
                     <content styleCode="underline">Storage</content>
                     <br/>  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original container. When product container is subdivided, repackage into a well-closed, light-resistance container.

 </paragraph>
               </text>
               <effectiveTime value="20240505"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="2f3344ca-419d-1e1b-e063-6394a90a426b"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <br/>
                  <paragraph>For the tablets, advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide). 
  <br/>  • Advise patients about the potential risk for serious neuropsychiatric symptoms and behavioral changes with montelukast sodium use
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.1</linkHtml>)].
 
  </content>
                     <br/>  • Discuss the benefits and risks of montelukast sodium with patients when prescribing or continuing treatment with montelukast sodium
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.1</linkHtml>)].
 
  </content>
                     <br/>  • Advise patients to monitor for changes in behavior or neuropsychiatric symptoms in patients taking montelukast sodium
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.1</linkHtml>)].
 
  </content>
                     <br/>  • Instruct patients to discontinue montelukast sodium and contact a healthcare provider immediately if changes in behavior or thinking that are not typical for the patient occur, or if the patient develops suicidal ideation or suicidal behavior
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.1</linkHtml>)].
 
  </content>
                     <br/>  • Advise patients to take montelukast sodium daily as prescribed, even when they are asymptomatic, as well as during periods of worsening asthma, and to contact their physicians if their asthma is not well controlled. 
  <br/>  • Advise patients that oral montelukast sodium is not for the treatment of acute asthma attacks. They should have appropriate short-acting inhaled β-agonist medication available to treat asthma exacerbations. Patients who have exacerbations of asthma after exercise should be instructed to have available for rescue a short-acting inhaled β-agonist. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.1">5.2</linkHtml>)].
 
  </content>
                     <br/>  • Advise patients to seek medical attention if short-acting inhaled bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for a 24-hour period are needed. 
  <br/>  • Instruct patients to continue other anti-asthma medications as prescribed unless instructed by a physician. 
  <br/>  • Instruct patients with known aspirin sensitivity to continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.3">5.4</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"> </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <br/>
                  <paragraph>Manufactured for: 
  <br/>  Quallent Pharmaceuticals Health LLC
 </paragraph>
                  <paragraph>Grand Cayman, Cayman Islands</paragraph>
                  <br/>
                  <paragraph>By:
 
  <content styleCode="bold">HETERO
  
   <sup>TM</sup>
                     </content>
                     <br/>  Hetero Labs Limited, Unit V, Polepally, Jadcherla, 
  <br/>  Mahabubnagar - 509 301, India.

 </paragraph>
                  <paragraph>Revised: 05/2024
 
  <content styleCode="italics">
                        <br/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240505"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>montelukastquallentlogo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="montelukastquallentlogo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_20">
               <id root="2f3344ca-419e-1e1b-e063-6394a90a426b"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Montelukast Sodium Tablets, USP</content>
                     <br/>
                     <content styleCode="bold">(mon” te loo’ kast soe’ dee um)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about montelukast sodium tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Serious mental health problems have happened in people taking montelukast sodium tablets</content>or even after treatment has stopped. This can happen in people with or without a history of mental health problems. Stop taking montelukast sodium tablets and tell your healthcare provider right away if you or your child have any unusual changes in behavior or thinking, including any of these symptoms:

 </paragraph>
                  <paragraph>• agitation, including aggressive behavior or hostility • hallucinations (seeing or hearing things that are not really there)  • suicidal thoughts and actions (including suicide) </paragraph>
                  <paragraph>• attention problems                                                    • memory problems                                                                 • tremor 
  <br/>  • bad or vivid dreams                                                  • obsessive-compulsive symptoms                                         • trouble sleeping 
  <br/>  • depression                                                                • restlessness                                                                         •uncontrolled muscle movements 
  <br/>  • disorientation (confusion)                                         • sleep walking 
  <br/>  • feeling anxious                                                         • stuttering  
  <br/>  • irritability 
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are montelukast sodium tablets?</content>
                  </paragraph>
                  <paragraph>Montelukast sodium tablets are a prescription medicine that blocks substances in the body called leukotrienes. This may help to improve symptoms of asthma and inflammation of the lining of the nose (allergic rhinitis). Montelukast sodium tablets do not contain a steroid. 
  <br/>  Montelukast sodium tablets are used to:
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">1.</content>  Prevent asthma attacks and for the long-term treatment of asthma in adults and adolescents ages 15 years and older. 
  <br/>
                     <content styleCode="bold">Do not take montelukast sodium tablets if you need relief right away for a sudden asthma attack.</content>If you have an asthma attack, you should follow the instructions your healthcare provider gave you for treating asthma attacks.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">2.</content>Prevent exercise-induced asthma in people 15 years of age and older. 
  <br/>
                     <content styleCode="bold">3.</content>Help control the symptoms of allergic rhinitis such as sneezing, stuffy nose, runny nose, and itching of the nose. Montelukast sodium tablets are used to treat the following in people who have already taken other medicines that did not work well enough or in people who could not tolerate other medicines: 
  <br/>  • outdoor allergies that happen part of the year (seasonal allergic rhinitis) in adults and adolescents ages 15 years and older,
 
  <content styleCode="bold">and</content>
                     <br/>  • indoor allergies that happen all year (perennial allergic rhinitis) in adults and adolescents ages 15 years and older.                                                    
  <br/>
                     <content styleCode="bold">Do not</content>take montelukast sodium tablets if you are allergic to any of its ingredients. See the end of this Medication Guide for a complete list of the ingredients in montelukast sodium tablets.                                                                                                                                                                         
  <br/>
                     <content styleCode="bold">Before taking montelukast sodium tablets, tell your healthcare provider about all your medical conditions, including if you:</content>
                  </paragraph>
                  <paragraph>• are allergic to aspirin. 
  <br/>  • have or have had mental health problems. 
  <br/>  • are pregnant or plan to become pregnant. Talk to your healthcare provider if you are pregnant or plan to become pregnant, montelukast sodium tablets may not be right for you. 
  <br/>  • are breastfeeding or plan to breastfeed. It is not known if montelukast sodium passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking montelukast sodium tablets.
 </paragraph>
                  <paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over the counter medicines, vitamins, and herbal supplements. Some medicines may affect how montelukast sodium tablets work, or montelukast sodium tablets may affect how your other medicines work.                                                                                                                                                                                                                 
  <br/>
                     <content styleCode="bold">How should I take montelukast sodium tablets?</content>
                  </paragraph>
                  <paragraph> For
 
  <content styleCode="bold">anyone</content>who takes montelukast sodium tablets: 
  <br/>  • Take montelukast sodium tablets exactly as prescribed by your healthcare provider. Your healthcare provider will tell you how much montelukast sodium tablets to take, and
 
  <content styleCode="bold">when to take it.</content>
                     <br/>  • Stop taking montelukast sodium tablets and tell your healthcare provider right away if you or your child have any unusual changes in behavior or thinking. 
  <br/>  • You can take montelukast sodium tablets with food or without food. 
  <br/>  •
 
  <content styleCode="bold">If you or your child misses a dose of montelukast sodium tablets, just take the next dose at your regular time.</content>Do not take 2 doses at the same time. 
  <br/>  • If you take too much montelukast sodium, call your healthcare provider right away. 
  <br/>
                     <content styleCode="bold">For adults and adolescents 15 years of age and older with asthma:</content>
                  </paragraph>
                  <paragraph>• Take montelukast sodium tablets 1 time each day, in the evening. Continue to take montelukast sodium tablets every day for as long as your healthcare provider prescribes it, even if you have no asthma symptoms. 
  <br/>  • Tell your healthcare provider right away if your asthma symptoms get worse, or if you need to use your rescue inhaler medicine more often for asthma attacks.
 </paragraph>
                  <paragraph>• Always have your rescue inhaler medicine with you for asthma attacks. 
  <br/>  • Continue to take your other asthma medicines as prescribed unless your healthcare provider tells you to change how you take these medicines. 
  <br/>
                     <content styleCode="bold">For people 15 years of age and older for the prevention of exercise-induced asthma:</content>
                     <br/>  • Take montelukast sodium tablets at least 2 hours before exercise. 
  <br/>  • Always have your rescue inhaler medicine with you for asthma attacks. 
  <br/>  • If you take montelukast sodium tablets every day for chronic asthma or allergic rhinitis,
 
  <content styleCode="bold">do not</content>take another dose to prevent exercise-induced asthma. Talk to your healthcare provider about your treatment for exercise-induced asthma. 
  <br/>
                     <content styleCode="bold">• Do not take 2 doses of montelukast sodium tablets within 24 hours (1 day).</content>
                     <br/>
                     <content styleCode="bold">For anyone 15 years of age and older with seasonal allergic rhinitis, or for anyone 15 years of age and older with perennial allergic rhinitis:</content>
                     <br/>  • Take montelukast sodium tablets 1 time each day, at about the same time each day.                                                                                                   
  <br/>
                     <content styleCode="bold">What should I avoid while taking montelukast sodium tablets?</content>
                     <br/>  If you have asthma and aspirin makes your asthma symptoms worse, continue to avoid taking aspirin or other medicines called non-steroidal anti-inflammatory drugs (NSAIDs) while taking montelukast sodium tablets.                                                                                                                           
  <br/>
                     <content styleCode="bold">What are the possible side effects of montelukast sodium tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Montelukast sodium tablets may cause serious side effects, including:</content>
                     <br/>  • See
 
  <content styleCode="bold">“What is the most important information I should know about montelukast sodium tablets?”</content>
                     <br/>
                     <content styleCode="bold">• Increase in certain white blood cells (eosinophils) and possible inflamed blood vessels throughout the body (systemic vasculitis).</content>Rarely, this can happen in people with asthma who take montelukast sodium tablets. This sometimes happens in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider right away if you get one or more of these  symptoms:</content>
                  </paragraph>
                  <paragraph>o a feeling of pins and needles or numbness of arms or legs  o rash 
  <br/>  o a flu-like illness  o severe inflammation (pain and swelling) of the sinuses (sinusitis)
 </paragraph>
                  <paragraph>
                     <content styleCode="bold"> The most common side effects of montelukast sodium tablets include:</content>
                  </paragraph>
                  <paragraph>• upper respiratory infection        • cough             • flu 
  <br/>  • fever                                         • stomach pain  • runny nose 
  <br/>  • headache                                 • diarrhea           • sinus infection 
  <br/>  • sore throat                                • earache or ear infection
 </paragraph>
                  <paragraph> These are not all the possible side effects of montelukast sodium tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.                                                                                                                                                                            
  <br/>
                     <content styleCode="bold">How should I store montelukast sodium tablets?</content>
                  </paragraph>
                  <paragraph>• Store montelukast sodium tablets at room temperature between 68°F to 77°F (20°C to 25°C). 
  <br/>  • Keep montelukast sodium tablets in the package they come in. 
  <br/>  • Keep montelukast sodium tablets in a dry place and keep it away from light. 
  <br/>
                     <content styleCode="bold">• Keep montelukast sodium tablets and all medicines out of reach of children. </content>                                                                                                    
  <br/>
                     <content styleCode="bold">General information about the safe and effective use of montelukast sodium tablets.</content>
                     <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use montelukast sodium tablets for a condition for which it was not prescribed. Do not give montelukast sodium tablets to other people even if they have the same symptoms you have. It may harm them. 
  <br/>  You can ask your pharmacist or healthcare provider for information about montelukast sodium tablets that is written for health professionals.             
  <br/>
                     <content styleCode="bold">What are the ingredients in montelukast sodium tablets?</content>
                     <br/>
                     <content styleCode="bold">Active ingredient:</content>montelukast sodium USP

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content>croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, mannitol and microcrystalline cellulose. The tablets are coated with opadry yellow which contains carnauba wax, hydroxypropyl cellulose, hypromellose, red iron oxide, titanium dioxide and yellow iron oxide.                                                                                                                                                                                            
  <br/>  For more information, call Quallent Pharmaceuticals Health LLC at 1-877-605-7243. 
  <br/>  Medication Guide available at
 
  <content styleCode="underline">https://www.quallentpharmaceuticals.com  </content>                  

 </paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM4"/>
                  <br/>
                  <paragraph>Manufactured for: 
  <br/>  Quallent Pharmaceuticals Health LLC
 </paragraph>
                  <paragraph>Grand Cayman, Cayman Islands</paragraph>
                  <br/>
                  <paragraph>By:
 
  <content styleCode="bold"> HETERO
  
   <sup>TM</sup>
                     </content>
                     <br/>  Hetero Labs Limited, Unit V, Polepally, Jadcherla, 
  <br/>  Mahabubnagar - 509 301, India.

 </paragraph>
                  <br/>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration 
  <br/>   Revised: 05/2024
 </paragraph>
               </text>
               <effectiveTime value="20240505"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>montelukastquallentlogo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="montelukastquallentlogo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="2f3344ca-419f-1e1b-e063-6394a90a426b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Montelukast Sodium Tablets, 10 mg - 1000's Count Container Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM5"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240505"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>montelukastcontainer1000scount</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="montelukastcontainer1000scount.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>